The overexpression of FOLR1 in gastric cancer opens avenues for targeted therapeutic strategies [22,23]. Folate receptor-targeted therapies, such as folate-drug conjugates and folate receptor-specific antibodies, have shown promise in preclinical models. This evidence concerns the gene FOLR1 and gastric cancer.